001461293 000__ 05226cam\a2200613\i\4500
001461293 001__ 1461293
001461293 003__ OCoLC
001461293 005__ 20230503003345.0
001461293 006__ m\\\\\o\\d\\\\\\\\
001461293 007__ cr\un\nnnunnun
001461293 008__ 230317s2023\\\\sz\a\\\\o\\\\\001\0\eng\d
001461293 019__ $$a1372398916
001461293 020__ $$a9783031158483$$q(electronic bk.)
001461293 020__ $$a3031158482$$q(electronic bk.)
001461293 020__ $$z9783031158476
001461293 020__ $$z3031158474
001461293 0247_ $$a10.1007/978-3-031-15848-3$$2doi
001461293 035__ $$aSP(OCoLC)1372322898
001461293 040__ $$aYDX$$beng$$erda$$epn$$cYDX$$dGW5XE$$dEBLCP$$dUKAHL
001461293 049__ $$aISEA
001461293 050_4 $$aRC159.A5
001461293 08204 $$a616.9/62061$$223/eng/20230317
001461293 24500 $$aMalarial drug delivery systems :$$badvances in treatment of infectious diseases /$$cRanjita Shegokar, Yashwant V. Pathak, editors.
001461293 264_1 $$aCham :$$bSpringer,$$c[2023]
001461293 264_4 $$c©2023
001461293 300__ $$a1 online resource (x, 395 pages) :$$billustrations (chiefly color)
001461293 336__ $$atext$$btxt$$2rdacontent
001461293 337__ $$acomputer$$bc$$2rdamedia
001461293 338__ $$aonline resource$$bcr$$2rdacarrier
001461293 500__ $$aIncludes index.
001461293 5050_ $$aMalaria: Cellular Understanding of Disease -- Drug Resistance, Statistics and Patent Status -- Malaria: Current Treatment Options -- Polymeric Nanoparticles in Malaria -- Solid Lipid Nanoparticles in Malaria -- Dendrimers in Malaria -- Liposomes in Malaria -- Micro and Nano Emulsions in Malaria -- Nanosuspension in Malaria -- Alginate and Gelatin Nanoparticles in Malaria -- Niosomes in Malaria -- Metal Nanoparticles in Malaria -- Nanotechnology in Malaria Diagnosis -- Nanotechnology-based Vaccination -- Herbal Platforms in Malaria -- Surface-modified Drug Delivery Systems in Malaria,- Clinical Trials in Malaria -- Malaria-Overall Picture -- New Drugs in Synthesis Research for Malaria -- Disease Models In Malaria Research.
001461293 506__ $$aAccess limited to authorized users.
001461293 520__ $$aThe disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause of significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, infectious diseases will undoubtedly persist as permanent and main threats to humanity for now and in the future, primarily due to increased longevity that almost always comes at the cost of impaired immunity. A total of four books are covered under the series of Infectious drug diseases. - Malarial drug delivery systems - Tubercular drug delivery systems - Viral drug delivery systems - Infectious disease drug delivery systems The theme of the first book is Malaria. This book compiles the complete road map of malarial drug delivery systems by understanding the pathophysiology of the disease, the current state of malaria across the globe, new clinical trials, emerging drugs, and the development of novel drug delivery platforms. Various novel micro-and nano-formulations using promising technologies are being explored to deliver the malarial drug via different administration routes. This book addresses the gap between new approaches and old treatment modalities and how the former is superior in pharmacological performance when tested in in-vitro and in-vivo. Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of malarial research.
001461293 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed March 17, 2023).
001461293 650_0 $$aMalaria$$xChemotherapy.
001461293 650_0 $$aDrug delivery systems.
001461293 655_0 $$aElectronic books.
001461293 7001_ $$aShegokar, Ranjita,$$eeditor.
001461293 7001_ $$aPathak, Yashwant Vishnupant,$$eeditor.
001461293 77608 $$iPrint version: $$z3031158474$$z9783031158476$$w(OCoLC)1337523659
001461293 852__ $$bebk
001461293 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-031-15848-3$$zOnline Access$$91397441.1
001461293 909CO $$ooai:library.usi.edu:1461293$$pGLOBAL_SET
001461293 980__ $$aBIB
001461293 980__ $$aEBOOK
001461293 982__ $$aEbook
001461293 983__ $$aOnline
001461293 994__ $$a92$$bISE